Mike Kratky, an analyst from Leerink Partners, reiterated the Buy rating on Tandem Diabetes Care (TNDM – Research Report). The associated price target remains the same with $49.00.
Mike Kratky has given his Buy rating due to a combination of factors that suggest a promising future for Tandem Diabetes Care despite recent setbacks. The significant drop in the company’s stock following the fourth-quarter earnings report has created a valuation that Kratky sees as particularly attractive, given the potential for growth. He notes that the sell-off has been disproportionate compared to the company’s actual performance, and believes that the current stock price already reflects a high level of investor caution for 2025.
Furthermore, Kratky highlights several underappreciated positives from the fourth-quarter earnings, such as the substantial portion of new starts coming from multiple daily injections (MDI) and the sequential growth in MDI starts expected throughout 2024. He also points to potential growth drivers, including pharmacy and Type 2 diabetes markets, and a favorable catalyst path. These factors, combined with management’s recent commentary, support his optimistic outlook and the decision to maintain a Buy rating with a price target of $49.
In another report released on March 10, Lake Street also maintained a Buy rating on the stock with a $75.00 price target.
TNDM’s price has also changed dramatically for the past six months – from $41.000 to $18.160, which is a -55.71% drop .